SG11201907443PA - Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders - Google Patents
Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disordersInfo
- Publication number
- SG11201907443PA SG11201907443PA SG11201907443PA SG11201907443PA SG11201907443PA SG 11201907443P A SG11201907443P A SG 11201907443PA SG 11201907443P A SG11201907443P A SG 11201907443PA SG 11201907443P A SG11201907443P A SG 11201907443PA SG 11201907443P A SG11201907443P A SG 11201907443PA
- Authority
- SG
- Singapore
- Prior art keywords
- taipei
- chien
- dist
- nei
- kang
- Prior art date
Links
- 230000002500 effect on skin Effects 0.000 title abstract 4
- 230000000495 immunoinflammatory effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 239000010154 weishu Substances 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448219P | 2017-01-19 | 2017-01-19 | |
| PCT/US2018/014366 WO2018136706A1 (en) | 2017-01-19 | 2018-01-19 | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907443PA true SG11201907443PA (en) | 2019-09-27 |
Family
ID=62838768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907443PA SG11201907443PA (en) | 2017-01-19 | 2018-01-19 | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10675260B2 (ja) |
| EP (1) | EP3570835B1 (ja) |
| JP (2) | JP2020505362A (ja) |
| KR (1) | KR102563841B1 (ja) |
| CN (2) | CN116919957A (ja) |
| CA (1) | CA3049450A1 (ja) |
| SG (1) | SG11201907443PA (ja) |
| TW (1) | TWI794200B (ja) |
| WO (1) | WO2018136706A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6535146B1 (ja) * | 2019-03-08 | 2019-06-26 | 佐藤製薬株式会社 | 皮膚バリア機能改善剤 |
| CN112679492B (zh) * | 2019-10-17 | 2022-03-18 | 中国科学院上海药物研究所 | 小檗碱衍生物、其制备方法和用途 |
| CN112538081A (zh) * | 2020-12-15 | 2021-03-23 | 辽宁中医药大学 | 一种源于黄柏盐炙品的巴马红汀及其分离制备方法和用途 |
| CN114236132B (zh) * | 2021-11-26 | 2024-02-02 | 李小光 | 一种用于检测人BP180 IgG抗体的ELISA试剂盒及其应用 |
| CN117257799A (zh) * | 2023-11-03 | 2023-12-22 | 云南中医药大学 | 巴马汀在制备治疗荨麻疹药物中的用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR026801A1 (es) * | 2000-01-12 | 2003-02-26 | Medidom Lab | Sustancias para uso en el tratamiento de la psoriasis |
| US6610750B1 (en) * | 2000-09-15 | 2003-08-26 | Laboratoires Negma | Treatment of osteoarthritis |
| CN100586428C (zh) * | 2001-11-02 | 2010-02-03 | 加州大学校务委员会 | 用于预防和治疗炎性疾病,自体免疫性疾病,和移植排斥的组成物及其制药用途 |
| KR20030082200A (ko) * | 2002-04-17 | 2003-10-22 | 주식회사 엘지생활건강 | 베르베린을 함유하는 아토피성 피부염 예방 및 완화용조성물 |
| FR2842738B1 (fr) * | 2002-07-23 | 2006-02-10 | Negma Lerads | Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus |
| TW200533369A (en) * | 2004-03-10 | 2005-10-16 | Pepgen Corp | Applications of treatment using interferon-tau |
| AU2005247403A1 (en) * | 2004-05-17 | 2005-12-08 | Combinatorx, Incorporated | Methods and reagents for the treatment of immunoinflammatory disorders |
| CN100441183C (zh) * | 2005-08-29 | 2008-12-10 | 中国医学科学院皮肤病研究所 | 盐酸13-己基小檗碱和盐酸13-己基巴马汀制备治疗湿疹、皮炎和银屑病的药物用途 |
| TWI473610B (zh) * | 2008-10-28 | 2015-02-21 | Twi Biotechnology Inc | 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物 |
| KR20170116231A (ko) * | 2009-06-30 | 2017-10-18 | 더만 바이오메디슨 코. 엘티디. | 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물 |
| WO2012160188A1 (en) * | 2011-05-26 | 2012-11-29 | Jado Technologies Gmbh | Hydroxy-substituted amino and ammonium derivatives and their medical use |
| US20140243354A1 (en) * | 2013-02-22 | 2014-08-28 | Galderma Research & Development Snc | Combinations of indigo naturalis and berberine and uses thereof |
| TW201538156A (zh) * | 2013-12-19 | 2015-10-16 | Twi Biotechnology Inc | 小蘗鹼配方及其用途 |
| KR102275267B1 (ko) * | 2014-01-25 | 2021-07-09 | 주식회사 엘지생활건강 | 피부 개선용 조성물 |
| CN103919777A (zh) * | 2014-05-04 | 2014-07-16 | 杨献华 | 一种防治银屑病的药物组合物及其应用 |
| EP3313520A4 (en) * | 2015-06-24 | 2019-01-02 | TWI Biotechnology, Inc. | Therapeutic uses of berberine formulations |
| CN117482078A (zh) * | 2015-07-01 | 2024-02-02 | 安成生物科技股份有限公司 | 双醋瑞因或大黄酸局部用制剂及其用途 |
-
2018
- 2018-01-19 EP EP18741264.8A patent/EP3570835B1/en active Active
- 2018-01-19 SG SG11201907443PA patent/SG11201907443PA/en unknown
- 2018-01-19 KR KR1020197023792A patent/KR102563841B1/ko active IP Right Grant
- 2018-01-19 CN CN202310291594.5A patent/CN116919957A/zh active Pending
- 2018-01-19 CN CN201880007670.2A patent/CN110191710B/zh active Active
- 2018-01-19 US US15/875,750 patent/US10675260B2/en active Active
- 2018-01-19 JP JP2019538676A patent/JP2020505362A/ja active Pending
- 2018-01-19 CA CA3049450A patent/CA3049450A1/en active Pending
- 2018-01-19 WO PCT/US2018/014366 patent/WO2018136706A1/en unknown
- 2018-01-19 TW TW107102071A patent/TWI794200B/zh active
-
2022
- 2022-03-04 JP JP2022033218A patent/JP7381629B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110191710A (zh) | 2019-08-30 |
| US20180200235A1 (en) | 2018-07-19 |
| JP2020505362A (ja) | 2020-02-20 |
| CN110191710B (zh) | 2023-04-18 |
| KR20190105070A (ko) | 2019-09-11 |
| WO2018136706A1 (en) | 2018-07-26 |
| KR102563841B1 (ko) | 2023-08-03 |
| EP3570835B1 (en) | 2023-08-09 |
| JP2022078204A (ja) | 2022-05-24 |
| US10675260B2 (en) | 2020-06-09 |
| CN116919957A (zh) | 2023-10-24 |
| EP3570835A4 (en) | 2021-03-03 |
| TWI794200B (zh) | 2023-03-01 |
| EP3570835A1 (en) | 2019-11-27 |
| TW201831474A (zh) | 2018-09-01 |
| JP7381629B2 (ja) | 2023-11-15 |
| CA3049450A1 (en) | 2018-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907443PA (en) | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201810210UA (en) | Engineered botulinum neurotoxins | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201805137XA (en) | Virus encoding an anti-tcr-complex antibody or fragment | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804721SA (en) | Modulators of complement activity | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases |